Verification between Original and Biosimilar Therapeutic Antibody Infliximab Using nSMOL Coupled LC-MS Bioanalysis in Human Serum

BACKGROUND: Infliximab (IFX) is a chimeric therapeutic monoclonal antibody targeting tumor necrosis factor alpha (TNFα)-mediated inflammatory immune diseases. However, despite of an initial good clinical response, decrease in response to long-term treatment is a common observation. OBJECTIVE: Recent...

Descripción completa

Detalles Bibliográficos
Autores principales: Iwamoto, Noriko, Yokoyama, Kotoko, Takanashi, Megumi, Yonezawa, Atsushi, Matsubara, Kazuo, Shimada, Takashi
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Bentham Science Publishers 2018
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6198460/
https://www.ncbi.nlm.nih.gov/pubmed/29968534
http://dx.doi.org/10.2174/1389201019666180703093517

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6198460/
https://www.ncbi.nlm.nih.gov/pubmed/29968534
http://dx.doi.org/10.2174/1389201019666180703093517

Ejemplares similares